Published on Jan 10, 2024
Australia is currently grappling with a resurgence of COVID-19 cases in 2024, primarily driven by the emergence of a new dominant strain called JN.1. This variant, stemming from BA.2.86, is characterized by a single spike protein mutation, L455S, which, despite its apparent minor nature, significantly amplifies the variant's transmissibility.
The impact of JN.1 is noteworthy as it specifically influences the virus's cell-binding component, enhancing its ability to evade antibodies. While its predecessor, BA.2.86, made its mark, it hadn't completely surmounted the challenge of navigating around the body's immune defenses.
JN.1 was first identified in the United States in September 2023. JN.1 caused nearly half of new U.S. coronavirus infections in the two weeks leading up to Christmas, the Centers for Disease Control and Prevention estimates.
According to CDC, the ongoing expansion of JN.1 implies that the variant may be either more transmissible or more proficient at evading our immune systems compared to other currently circulating variants. At this stage, it remains too early to determine whether and to what extent JN.1 will contribute to an increase in infections or hospitalizations.
As of today in Australia, Victoria is confronting a dual wave of COVID-19, a situation attributed by health authorities to the rapid spread of the JN.1 variant. This novel variant has instigated a second wave of infections, leading to a notable increase in coronavirus-related hospitalizations. Meanwhile, in New South Wales (NSW), the state is grappling with the "highest level of COVID-19" within the community in the past year. The predominant source of infections is linked to Omicron-related variants, with JN.1 accounting for 35 percent of infections and the EG.5 variant contributing to 40 percent, as reported by NSW Health.
The World Health Organization (WHO) has designated JN.1 as a variant of interest with a low associated risk, despite its increased transmissibility. Notably, the severity of JN.1 remains relatively low, offering some reassurance amidst concerns about its prevalence. Although Australia has experienced a rise in COVID-19 hospitalizations, the increase is more attributed to the growing number of cases than to a surge in severity according the experts.
However, COVID-19 continues to pose a significant public health risk, particularly for individuals with an elevated susceptibility to severe illness, including older adults, infants, and those with specific disabilities or underlying health conditions.
According to the CDC, the signs and symptoms of NJ.1 are not known to be different from those associated with previous strains. These include a sore throat, cough, fever, congestion, and runny nose, along with fatigue and muscle aches.
To address the ongoing challenges of this evolving situation, the Department of Health Victoria recommends six precautionary measures:
If you need to take a day or two off due to common cold, you can conveniently request a medical certificate online from the comfort of your couch at NextClinic. Our team of Australian-registered doctors will promptly review your request and approve it within one hour, allowing you to rest and recover quickly.
This medical blog provides general information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your regular doctor for specific medical concerns. The content is based on the knowledge available at the time of publication and may change. While we strive for accuracy, we make no warranties regarding completeness or reliability. Use the information at your own risk. Links to other websites are provided for convenience and do not imply endorsement. The views expressed are those of the authors and not necessarily representative of any institutions.